Research Article: Bronchodilator Responsiveness Measured by Spirometry and Impulse Oscillometry in Patients with Asthma After Short Acting Antimuscarinic and/or Beta--Agonists Inhalation
Abstract:
Bronchodilator responsiveness (BDR) in asthma (previously often called “reversibility”) generally refers to rapid improvements in forced expiratory volume in second (FEV) measured within minutes after inhalation of a short-acting bronchodilator., Depending on the cohort, –% of asthma patients demonstrate BDR when tested using short-acting beta--agonist (SABA)., Regular use of SABA leads to increased beta--receptor tolerance, reduced response to the medication, and increased allergen response and inflammation, therefore, it is no longer recommended as a single reliever medication. Instead, the Global Initiative for Asthma (GINA)-guidelines () recommend mild asthma symptoms are relieved, when necessary, with low-dose inhaled corticosteroids (ICS) and formoterol (a long-acting beta--agonists, LABA, with relative rapid onset of action), moderate asthma should also take this combination daily (ie maintenance and reliever), while LAMA is only considered in more severe asthma (ie step ). In general, most patients with BDR in asthma control their symptoms with ICS+LABA (ie mild-moderate severity); however, since BDR is an indication that the airway smooth muscle is targetable, maybe antimuscarines should be considered before step .
Introduction:
Bronchodilator responsiveness (BDR) in asthma (previously often called “reversibility”) generally refers to rapid improvements in forced expiratory volume in second (FEV ) measured within minutes after inhalation of a short-acting bronchodilator. , Depending on the cohort, –% of asthma patients demonstrate BDR when tested using short-acting beta--agonist (SABA). , Regular use of SABA leads to increased beta--receptor tolerance, reduced response to the medication, and increased allergen response and inflammation,…
Read more